INT53476

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 1994
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 6
Total Number 8
Disease Relevance 2.88
Pain Relevance 2.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nuclear envelope (Ptgs1) aging (Ptgs1) Golgi apparatus (Ptgs1)
endoplasmic reticulum (Ptgs1) cytoplasm (Ptgs1) lipid binding (Ptgs1)
Anatomy Link Frequency
spinal 2
Ptgs1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cOX1 4 100.00 Very High Very High Very High
COX2 4 100.00 Very High Very High Very High
Pain 4 100.00 Very High Very High Very High
substance P 1 100.00 Very High Very High Very High
Hyperalgesia 3 99.68 Very High Very High Very High
Spinal cord 6 94.88 High High
antagonist 16 94.80 High High
Painful diabetic neuropathy 6 93.92 High High
bradykinin 1 92.04 High High
agonist 6 91.84 High High
Disease Link Frequency Relevance Heat
Hyperalgesia 12 99.68 Very High Very High Very High
Diabetes Mellitus 18 99.40 Very High Very High Very High
Cv General 3 Under Development 2 97.28 Very High Very High Very High
Overactive Bladder 6 95.52 Very High Very High Very High
Diabetic Neuropathy 6 93.92 High High
Hemolysis 2 87.00 High High
Anaphylaxis 2 69.04 Quite High
Pain 1 41.28 Quite Low
Pollakiuria 2 5.00 Very Low Very Low Very Low
INFLAMMATION 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Positive_regulation (cumulative) of Localization (administration) of cyclooxygenase-1
1) Confidence 0.49 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
MATERIALS AND METHODS: Cerebral infarcted rats underwent cumulative intravenous administration of the selective cyclooxygenase-1 inhibitor SC-560 (Sigma), the selective cyclooxygenase-2 inhibitor rofecoxib (Kemprotec, Middlesbrough, United Kingdom) or the nonselective cyclooxygenase inhibitor FYO-750 hourly plus a single intravenous administration of SC-560, rofecoxib or SC-560 plus rofecoxib.
Positive_regulation (cumulative) of Localization (administration) of cyclooxygenase
2) Confidence 0.49 Published 2010 Journal J. Urol. Section Body Doc Link 20022033 Disease Relevance 0.19 Pain Relevance 0
Hyperalgesic behavior in diabetic rats is associated with both increased cyclooxygenase-2 protein and cyclooxygenase-mediated PGE(2) release.
Positive_regulation (increased) of Localization (release) of cyclooxygenase associated with hyperalgesia and diabetes mellitus
3) Confidence 0.45 Published 2002 Journal Diabetes Section Abstract Doc Link 12086957 Disease Relevance 0.72 Pain Relevance 0.47
Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats.
Positive_regulation (Elevated) of Localization (release) of cyclooxygenase in spinal associated with hyperalgesia, diabetes mellitus and cox1
4) Confidence 0.45 Published 2002 Journal Diabetes Section Title Doc Link 12086957 Disease Relevance 0.75 Pain Relevance 0.55
Hyperalgesic behavior in diabetic rats is associated with both increased cyclooxygenase-2 protein and cyclooxygenase-mediated PGE(2) release.
Positive_regulation (increased) of Localization (release) of cyclooxygenase associated with hyperalgesia and diabetes mellitus
5) Confidence 0.45 Published 2002 Journal Diabetes Section Abstract Doc Link 12086957 Disease Relevance 0.72 Pain Relevance 0.47
These results suggest that stonefish venom may cause the release of acetylcholine, substance P, and cyclooxygenase products, or contain components which act at these receptors.
Spec (may) Positive_regulation (cause) of Localization (release) of cyclooxygenase associated with substance p
6) Confidence 0.26 Published 1994 Journal Toxicon Section Abstract Doc Link 7846690 Disease Relevance 0.06 Pain Relevance 0.29
In addition the venom was found to cause the release of cyclooxygenase products and to contain a heat-sensitive hemolytic factor.
Positive_regulation (cause) of Localization (release) of cyclooxygenase
7) Confidence 0.21 Published 1994 Journal Nat. Toxins Section Abstract Doc Link 8032693 Disease Relevance 0.24 Pain Relevance 0.07
Involvement of constitutive (COX-1) and inducible cyclooxygenase (COX-2) in the adrenergic-induced ACTH and corticosterone secretion.
Positive_regulation (adrenergic-induced) of Localization (secretion) of cyclooxygenase associated with cox1
8) Confidence 0.15 Published 2001 Journal J. Physiol. Pharmacol. Section Title Doc Link 11785774 Disease Relevance 0 Pain Relevance 0.49

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox